• Something wrong with this record ?

Examining the Relationship and Prognostic Significance of Cell-Free DNA Levels and the PSMA-Positive Tumor Volume in Men with Prostate Cancer: A Retrospective-Prospective [68Ga]Ga-PSMA-11 PET/CT Study

K. Kluge, H. Einspieler, D. Haberl, C. Spielvogel, S. Stoiber, C. Vraka, L. Papp, S. Wunsch, G. Egger, G. Kramer, B. Grubmüller, S. Shariat, M. Hacker, L. Kenner, A. Haug

. 2024 ; 65 (1) : 63-70. [pub] 20240102

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24007671

Functional imaging with prostate-specific membrane antigen (PSMA) ligands has emerged as the standard imaging method for prostate cancer (PCA). In parallel, the analysis of blood-derived, cell-free DNA (cfDNA) has been shown to be a promising quantitative biomarker of PCA aggressiveness and patient outcome. This study aimed to evaluate the relationship and prognostic value of cfDNA concentrations and the PSMA-positive tumor volume (PSMA-TV) in men with PCA undergoing [68Ga]Ga-PSMA-11 PET/CT imaging. Methods: We recruited 148 men with histologically proven PCA (mean age, 70.7 ± 7.7 y) who underwent [68Ga]Ga-PSMA-11 PET/CT (184.9 ± 18.9 MBq) and blood sampling between March 2019 and August 2021. Among these, 74 (50.0%) had hormone-sensitive PCA and 74 (50.0%) had castration-resistant PCA (CRPC). All patients provided written informed consent before blood sample collection and imaging. The cfDNA was extracted and quantified, and PSMA-expressing tumor lesions were delineated to extract the PSMA-TVs. The Spearman coefficient assessed correlations between PSMA-TV and cfDNA concentrations and cfDNA's relation with clinical parameters. The Kruskal-Wallis test examined the mean cfDNA concentration differences based on PSMA-TV quartiles for significantly correlated patient groups. Log-rank and multivariate Cox regression analyses evaluated the prognostic significance of high and low cfDNA and PSMA-TV levels for overall survival. Results: Weak positive correlations were found between cfDNA concentration and PSMA-TV in the overall group (r = 0.16, P = 0.049) and the CRPC group (r = 0.31, P = 0.007) but not in hormone-sensitive PCA patients (r = -0.024, P = 0.837). In the CRPC cohort, cfDNA concentrations significantly differed between PSMA-TV quartiles 4 and 1 (P = 0.002) and between quartiles 4 and 2 (P = 0.016). Survival outcomes were associated with PSMA-TV (P < 0.0001, P = 0.004) but not cfDNA (P = 0.174, P = 0.12), as per the log-rank and Cox regression analysis. Conclusion: These findings suggest that cfDNA might serve as a biomarker of advanced, aggressive CRPC but does not reliably reflect total tumor burden or prognosis. In comparison, [68Ga]Ga-PSMA-11 PET/CT provides a highly granular and prognostic assessment of tumor burden across the spectrum of PCA disease progression.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007671
003      
CZ-PrNML
005      
20240423160155.0
007      
ta
008      
240412s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.2967/jnumed.123.266158 $2 doi
035    __
$a (PubMed)38050125
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kluge, Kilian $u Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria $u Christian Doppler Laboratory for Applied Metabolomics, Medical University of Vienna, Vienna, Austria
245    10
$a Examining the Relationship and Prognostic Significance of Cell-Free DNA Levels and the PSMA-Positive Tumor Volume in Men with Prostate Cancer: A Retrospective-Prospective [68Ga]Ga-PSMA-11 PET/CT Study / $c K. Kluge, H. Einspieler, D. Haberl, C. Spielvogel, S. Stoiber, C. Vraka, L. Papp, S. Wunsch, G. Egger, G. Kramer, B. Grubmüller, S. Shariat, M. Hacker, L. Kenner, A. Haug
520    9_
$a Functional imaging with prostate-specific membrane antigen (PSMA) ligands has emerged as the standard imaging method for prostate cancer (PCA). In parallel, the analysis of blood-derived, cell-free DNA (cfDNA) has been shown to be a promising quantitative biomarker of PCA aggressiveness and patient outcome. This study aimed to evaluate the relationship and prognostic value of cfDNA concentrations and the PSMA-positive tumor volume (PSMA-TV) in men with PCA undergoing [68Ga]Ga-PSMA-11 PET/CT imaging. Methods: We recruited 148 men with histologically proven PCA (mean age, 70.7 ± 7.7 y) who underwent [68Ga]Ga-PSMA-11 PET/CT (184.9 ± 18.9 MBq) and blood sampling between March 2019 and August 2021. Among these, 74 (50.0%) had hormone-sensitive PCA and 74 (50.0%) had castration-resistant PCA (CRPC). All patients provided written informed consent before blood sample collection and imaging. The cfDNA was extracted and quantified, and PSMA-expressing tumor lesions were delineated to extract the PSMA-TVs. The Spearman coefficient assessed correlations between PSMA-TV and cfDNA concentrations and cfDNA's relation with clinical parameters. The Kruskal-Wallis test examined the mean cfDNA concentration differences based on PSMA-TV quartiles for significantly correlated patient groups. Log-rank and multivariate Cox regression analyses evaluated the prognostic significance of high and low cfDNA and PSMA-TV levels for overall survival. Results: Weak positive correlations were found between cfDNA concentration and PSMA-TV in the overall group (r = 0.16, P = 0.049) and the CRPC group (r = 0.31, P = 0.007) but not in hormone-sensitive PCA patients (r = -0.024, P = 0.837). In the CRPC cohort, cfDNA concentrations significantly differed between PSMA-TV quartiles 4 and 1 (P = 0.002) and between quartiles 4 and 2 (P = 0.016). Survival outcomes were associated with PSMA-TV (P < 0.0001, P = 0.004) but not cfDNA (P = 0.174, P = 0.12), as per the log-rank and Cox regression analysis. Conclusion: These findings suggest that cfDNA might serve as a biomarker of advanced, aggressive CRPC but does not reliably reflect total tumor burden or prognosis. In comparison, [68Ga]Ga-PSMA-11 PET/CT provides a highly granular and prognostic assessment of tumor burden across the spectrum of PCA disease progression.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    _2
$a radioizotopy galia $7 D005710
650    _2
$a PET/CT $x metody $7 D000072078
650    _2
$a prognóza $7 D011379
650    12
$a nádory prostaty rezistentní na kastraci $x diagnostické zobrazování $7 D064129
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a tumor burden $7 D047368
650    _2
$a prospektivní studie $7 D011446
650    _2
$a izotopy gallia $7 D005709
650    12
$a nádory prostaty $x diagnostické zobrazování $x patologie $7 D011471
650    _2
$a biologické markery $7 D015415
650    12
$a volné cirkulující nukleové kyseliny $7 D000073888
650    _2
$a hormony $7 D006728
650    _2
$a EDTA $7 D004492
655    _2
$a časopisecké články $7 D016428
700    1_
$a Einspieler, Holger $u Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
700    1_
$a Haberl, David $u Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
700    1_
$a Spielvogel, Clemens $u Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria $u Christian Doppler Laboratory for Applied Metabolomics, Medical University of Vienna, Vienna, Austria
700    1_
$a Stoiber, Stefan $u Christian Doppler Laboratory for Applied Metabolomics, Medical University of Vienna, Vienna, Austria $u Department of Pathology, Medical University of Vienna, Vienna, Austria
700    1_
$a Vraka, Chrysoula $u Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
700    1_
$a Papp, Laszlo $u Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria
700    1_
$a Wunsch, Sabine $u Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
700    1_
$a Egger, Gerda $u Department of Pathology, Medical University of Vienna, Vienna, Austria
700    1_
$a Kramer, Gero $u Department of Urology, Medical University of Vienna, Vienna, Austria
700    1_
$a Grubmüller, Bernhard $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology and Andrology, University Hospital Krems, Krems, Austria $u Karl Landsteiner University of Health Sciences, Krems, Austria
700    1_
$a Shariat, Shahrokh $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology and Andrology, University Hospital Krems, Krems, Austria $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas $u Division of Urology, Department of Special Surgery, University of Jordan, Amman, Jordan $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; and $u Department of Urology, Weill Cornell Medical College, New York, New York
700    1_
$a Hacker, Marcus $u Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
700    1_
$a Kenner, Lukas $u Christian Doppler Laboratory for Applied Metabolomics, Medical University of Vienna, Vienna, Austria $u Department of Pathology, Medical University of Vienna, Vienna, Austria
700    1_
$a Haug, Alexander $u Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria; alexander.haug@meduniwien.ac.at $u Christian Doppler Laboratory for Applied Metabolomics, Medical University of Vienna, Vienna, Austria
773    0_
$w MED00010072 $t The Journal of nuclear medicine $x 1535-5667 $g Roč. 65, č. 1 (2024), s. 63-70
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38050125 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423160151 $b ABA008
999    __
$a ok $b bmc $g 2081577 $s 1217438
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 65 $c 1 $d 63-70 $e 20240102 $i 1535-5667 $m The Journal of nuclear medicine $n J Nucl Med $x MED00010072
LZP    __
$a Pubmed-20240412

Find record

Citation metrics

Archiving options